Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
UBS
Cerilliant
Novartis
Covington
Dow
Moodys
Queensland Health
Cantor Fitzgerald
Daiichi Sankyo

Generated: January 22, 2018

DrugPatentWatch Database Preview

ZEMPLAR Drug Profile

« Back to Dashboard

When do Zemplar patents expire, and what generic alternatives are available?

Zemplar is a drug marketed by Abbvie and is included in two NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has seventeen patent family members in ten countries.

The generic ingredient in ZEMPLAR is paricalcitol. There are ten drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the paricalcitol profile page.
Summary for ZEMPLAR
Drug patent expirations by year for ZEMPLAR
Pharmacology for ZEMPLAR
Ingredient-typeCholecalciferol
Drug ClassVitamin D3 Analog

US Patents and Regulatory Information for ZEMPLAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-001 May 26, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-003 May 26, 2005 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-002 May 26, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-001 Apr 17, 1998 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-003 May 26, 2005 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-003 Feb 1, 2000 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-001 May 26, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-002 May 26, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-002 Feb 1, 2000 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-003 Feb 1, 2000 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ZEMPLAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-001 Apr 17, 1998 ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-002 May 26, 2005 ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-002 May 26, 2005 ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-001 May 26, 2005 ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-003 May 26, 2005 ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-002 Feb 1, 2000 ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-003 May 26, 2005 ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-001 Apr 17, 1998 ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-003 Feb 1, 2000 ➤ Subscribe ➤ Subscribe
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-001 May 26, 2005 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ZEMPLAR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 11/28/2008
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 10/14/2008
➤ Subscribe Capsules 4 mcg ➤ Subscribe 8/25/2008

International Patents for ZEMPLAR

Supplementary Protection Certificates for ZEMPLAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/003 United Kingdom ➤ Subscribe PRODUCT NAME: PARICALCITOL; REGISTERED: ES SPAIN 64.974 20020809; UK PL 00037/0403 20030721
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Boehringer Ingelheim
Citi
Mallinckrodt
AstraZeneca
Healthtrust
McKinsey
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot